Investor
This Series C comes less than a year after the startup closed its $200 million Series B in 2020.
Funding will be used to push for regulatory approval of its flagship synthetic implant product.
The company also revealed new partnerships with AdvancedMd, DrChrono and athenahealth.
The company boasted strong revenues and membership growth but took a hit in its GAAP net income.
The acquisition allows cliexa to meet GI customers with an end-to-end automated scheduling, reporting and communications platform.
The company currently has 11 locations delivering virtual-supported care, but now plans to open "several" more in the first half of 2021.
This merger comes over a year after news broke that Outcome Health faced a number of legal battles.
The company's technology looks to reduce the burden on pathologists reviewing digital slides, while also serving as a safety net to reduce errors.
The startup will now move onto a larger pivotal trial of the neuromodulation therapy, which received a Breakthrough Device Designation from the FDA in January.
The deal is expected to close in the second quarter of 2021. It will value the combined company at approximately $1.1 billion.